U.S. Markets open in 9 hrs 11 mins

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.25-0.67 (-3.74%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
    Business Wire

    Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

    Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 12:45 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.

  • Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma
    Business Wire

    Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma

    Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the publication of a peer-reviewed paper in eLife, a science journal, entitled, "Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis." This paper evaluates the treatment effect of netarsudil, marketed as Rhopressa® (netarsudil ophthalmic solution) 0.02% in the United States, on steroid-induced ocular hypertension in a mouse model and steroid-induced glaucoma in humans.

  • Aerie (AERI) Up 11.8% Since Last Earnings Report: Can It Continue?
    Zacks

    Aerie (AERI) Up 11.8% Since Last Earnings Report: Can It Continue?

    Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.